Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study involves people with haemophilia A, a condition where blood does not clot properly because the body lacks enough of a specific clotting protein. This condition can occur with or without the presence of inhibitors, which are substances in the blood that can block the clotting protein from working. The study will use a medication called denecimig, also known by its code name NNC0365-3769 or Mim8, which is given as an injection under the skin. Participants will be switching from their current medication called emicizumab to the study medication.

The purpose of this study is to look at how safe it is for people with haemophilia A to switch from emicizumab to Mim8. The study will observe what happens during the time when emicizumab is leaving the body while people are starting treatment with Mim8. This includes watching for any unwanted effects that might occur during this switch.

During the study, participants will receive Mim8 injections under the skin for up to 26 weeks. They will need to attend regular visits and keep track of their experiences using an electronic diary. The study will also ask participants to complete questionnaires about how they find using the injection device and how the treatment affects their daily life. The study involves adults and adolescents aged 12 years and older who have been taking emicizumab for at least 8 weeks and who have decided with their doctor to stop taking emicizumab.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Starting treatment with Mim8

    Upon joining the study, treatment with Mim8 (denecimig) will begin. This medication is administered as a subcutaneous injection, which means it is injected under the skin.

    The study involves switching directly from previous treatment with emicizumab to Mim8. During this transition period, the emicizumab will gradually leave the body, a process called washout.

    Mim8 is provided as a solution for injection and will be used for preventive treatment, also known as prophylaxis, to reduce bleeding episodes.

  2. Step 2

    Regular monitoring and safety assessments

    Throughout the study, regular monitoring will take place to evaluate the safety of Mim8 treatment during the period when emicizumab is leaving the body.

    Any treatment-emergent adverse events, which are unwanted medical occurrences that happen during treatment, will be recorded and assessed.

    Scheduled visits will be required to track health status and ensure the treatment is proceeding safely.

  3. Step 3

    Completing questionnaires and diary entries

    An electronic diary will need to be completed regularly to record information about treatment and any symptoms or events.

    The haemophilia device assessment tool questionnaire will be completed to evaluate experience with handling the injection device.

    The haemophilia treatment experience measure questionnaire will be completed to assess any changes in treatment burden, which refers to the impact and effort involved in managing the treatment.

  4. Step 4

    Continuing prophylaxis treatment

    Mim8 prophylaxis treatment will continue throughout the study period to prevent bleeding episodes.

    The study is designed to assess the safety of this treatment approach in individuals with haemophilia A, a bleeding disorder caused by a lack of coagulation factor VIII, a protein that helps blood clot.

    This applies to individuals both with and without FVIII inhibitors, which are antibodies that can interfere with clotting factor treatment.

  5. Step 5

    Study completion

    The study will continue until the estimated completion date in February 2025.

    Final assessments will be conducted to evaluate the overall safety experience with Mim8 during the transition from emicizumab treatment.

Who can join the trial?

6 criteria

  • You must provide your informed consent (agreement to participate) before any study activities begin. Study activities are any procedures done as part of the study, including tests to see if you are suitable.
  • You must be male or female with a diagnosis of congenital haemophilia A (a bleeding disorder you were born with that affects blood clotting) of any severity, confirmed in your medical records.
  • You must be 12 years of age or older at the time you sign the consent form.
  • You must have been treated with emicizumab (a medicine used to prevent bleeding episodes) given once weekly, once every two weeks, or once every four weeks as prescribed for at least 8 weeks before the screening visit.
  • The decision to stop your emicizumab treatment must have already been made by your doctor.
  • You and your caregiver (if applicable) must be willing and able to follow the study schedule and complete all study procedures, including filling out an electronic diary (a digital record of your health information) and questionnaires about your health.

Who cannot join the trial?

2 criteria

  • The source data does not contain specific exclusion criteria (reasons why a patient cannot participate in the study) for this clinical trial.
  • If you are interested in participating, the research team will need to evaluate your individual medical situation to determine if you meet all requirements for participation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Mim8

    (also known as NNC0365-3769) is an investigational medication being studied as a preventive treatment for hemophilia A. It is designed to help blood clot properly in people with hemophilia A, whether or not they have developed inhibitors (antibodies that block standard treatments). In this trial, participants are switching from their current preventive medication to Mim8 to see how safe it is during the transition period.

  • Emicizumab

    is a medication used to prevent bleeding episodes in people with hemophilia A. It works by helping the blood clotting process in patients whose bodies may not produce enough clotting factor or who have developed inhibitors. In this study, participants were previously receiving emicizumab as their regular preventive treatment before switching to the investigational medication.

What is already known about the treatment

Mim8 – Mim8 is an experimental medication currently being studied in clinical trials for the prevention of bleeding episodes in people with Hemophilia A, a genetic disorder where blood does not clot properly due to missing or low levels of clotting factor VIII. This drug is designed to work as a prophylactic treatment, meaning it is given regularly to prevent bleeding before it occurs, and it is being tested specifically in patients who are switching from another preventive medication called emicizumab. Mim8 works by mimicking the function of factor VIII in the blood clotting process, helping to bring together the necessary clotting factors at a molecular level so that blood can clot normally even when factor VIII is absent or not working properly.

Investigated diseases

Haemophilia A – Haemophilia A is a bleeding disorder caused by a lack of clotting factor VIII in the blood. People with this condition experience prolonged bleeding because their blood does not clot properly. The disease is inherited and passed from parents to children through genes. Bleeding can occur after injuries or surgeries, but sometimes it happens spontaneously without any obvious cause. Internal bleeding into joints and muscles is common and can cause pain and swelling. Over time, repeated bleeding into joints can lead to joint damage and reduced movement.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502450-13-00Protocol codeNN7769-4728Estimated enrolment60 patientsSponsorNovo Nordisk A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.